Echos in PsA, RA: 🔹Diastolic dysfxn: 52% of PsA and RA (!), controls 5% 🔹Mitral regurge PsA 84%, Ra 53%, controls 10% 🔹Mild pulmonary valve regurge higher in PsA (Diastolic dysfxn has been seen in prior RA studies) https://t.co/QCKR5itfYj #ACR21 Abst1308 @RheumNow

• Higher Prevalence of Echocardiographic Abnormalities in Psoriatic Arthritis and…

Supporting date for Ixekizumab in PsA with symptoms of axial involvement. 🔹Improvement in QoL (SF-36), ASDAS, BASDAI50 🔹Maintained at 52 weeks 🔹Stricter criteria (younger, ⬆️CRP) showed similar results https://t.co/QSJLQTxLcW #ACR21 Abst#3147 @RheumNow

• Ixekizumab Efficacy in Patients with Psoriatic Arthritis Presenting with Sympto…

Dr Oster presenting on IL-23 inhibitor Risankizumab in PsA. No surprises here, it works. We need comparative efficacy trials! Abstr#0453 #ACR21 @RheumNow https://t.co/mj8TeCqEcg

Year 2 f/u on PsA, axSpA, or RA using CT-P13, an infliximab (IFX) biosimilar. Pts either naive to IFX or switched from IFX: 💠IFX-naive: improved disease activity 💠IFX-switched: maintained stable disease 💠No new safety concerns https://t.co/VGBicnq15w #ACR21 Abst#0817 @RheumNow

• Biosimilar Infliximab Therapy in Rheumatoid Arthritis, Axial Spondyloarthritis …

Dr. Eric Ruderman gives his perspective on PsA data presented during the plenary session on Saturday at the #ACR21 annual meeting. https://t.co/r9FgBO6VT7 https://t.co/JbV519XQoG

• https://bit.ly/3kcOt0c